Search

Author/Creator Grieve, Robert

1. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Issue 10191 (29th June 2019)

Authors:
Earl, Helena M; Hiller, Louise; Vallier, Anne-Laure; Loi, Shrushma; McAdam, Karen; Hughes-Davies, Luke; Harnett, Adrian N; Ah-See, Mei-Lin; Simcock, Richard; Rea, Daniel; Raj, Sanjay; Woodings, Pamela; Harries, Mark; Howe, Donna; Raynes, Kerry; Higgins, Helen B; Wilcox, Maggie; Plummer, Chris; Ma...
Journal:
Lancet
Issue:
Volume 393:Issue 10191(2019)
Page Start:
2599
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB): A randomised, phase III, trial. (January 2020)

Authors:
Fernando, Indrajit N.; Bowden, Sarah J.; Herring, Kathryn; Brookes, Cassandra L.; Ahmed, Ikhlaaq; Marshall, Andrea; Grieve, Robert; Churn, Mark; Spooner, David; Latief, Talaat N.; Agrawal, Rajiv K.; Brunt, Adrian M.; Stevens, Andrea; Goodman, Andrew; Canney, Peter; Bishop, Jill; Ritchie, Diana; D...
Journal:
Radiotherapy and oncology
Issue:
Volume 142(2020)
Page Start:
52
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗